Search results
Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher
Zacks via Yahoo Finance· 9 months agoAfter losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc....
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
Zacks via Yahoo Finance· 7 months agoIf you are looking for stocks that have gained strong momentum recently but are still trading at...
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 month agoVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript March 28, 2024 Vivos...
The Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analyst Just Cut Their Revenue Forecast By 14%
Simply Wall St. via Yahoo Finance· 1 year agoToday is shaping up negative for Vivos Therapeutics, Inc. (NASDAQ:VVOS) shareholders, with the...
Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 1 month agoVivos Therapeutics (NASDAQ:VVOS) Full Year 2023 Results Key Financial Results Revenue: US$13.8m...
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Screens Well But There Might Be A Catch
Simply Wall St. via Yahoo Finance· 9 months agoWith a median price-to-sales (or "P/S") ratio of close to 1.1x in the Healthcare industry in the...
Vivos Therapeutics First Quarter 2022 Earnings: Revenues Disappoint
Simply Wall St. via Yahoo Finance· 1 year agoVivos Therapeutics (NASDAQ:VVOS) First Quarter 2022 Results Key Financial Results Revenue: US$3.46m...
A Headache-Free Future? Vivos' POD Device Slashes Migraine Symptoms by 89% in Clinical Study
Benzinga via Yahoo Finance· 1 year agoVivos Therapeutics Inc (NASDAQ: VVOS) announced the results of a recent clinical observational study...
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Just Slashed This Year's Estimates
Simply Wall St. via Yahoo Finance· 2 years agoThe analysts covering Vivos Therapeutics, Inc. (NASDAQ:VVOS) delivered a dose of negativity to...
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 11 months agoVivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.20 per share versus the Zacks...